Tuberculosis and neglected diseases targeted by new center

A major new centre to boost the development of drugs to tackle the foremost diseases of the developing world is to be created at the University of Dundee.

There is an urgent need for new drugs to treat of the developing world, such as (TB), and . However, despite significant efforts in early stage drug discovery, there is a bottleneck when it comes to the lead optimisation stage of molecules targeting these diseases.

Lead optimisation is a key stage in the drug discovery process, where early leads are improved through cycles of design, synthesis and testing to identify potential drugs which are suitable for testing in a clinical setting. It is a labour intensive process requiring significant laboratory resource over a number of years.

To address this need Professor Paul Wyatt and colleagues at the Drug Discovery Unit (DDU) at the University of Dundee, with joint funding from the Wellcome Trust and the Bill & Melinda Gates Foundation, are establishing "A Centre of Excellence for Lead Optimisation for Diseases of the Developing World". The Dundee centre represents a £6.5million investment over five years and will create 11 new posts.

Professor Wyatt said, "One of the main aims of the Drug Discovery Unit is to make inroads into developing drugs for diseases that affected the developing world. We have the capability through the DDU to help break the bottleneck which occurs at a key stage of the drug discovery process."

The initial focus will be on TB, the world's second-leading infectious killer, disproportionately affecting developing countries; in 2010 causing 1.4 million deaths, 8.8 million new infections and 450 thousand drug-resistant TB cases. First-line therapies for TB are old and inadequate, taking six months to cure patients. The long treatment regimen contributes to high treatment default rates that can lead to increased disease transmission, drug resistance, and death.

The strategy is to identify a portfolio of TB Lead Optimisation projects through the DDU's involvement with the global HIT-TB consortium and TB Drug Accelerator Program which are working to generate drug leads through their screening programmes.

The DDU as part of HIT-TB is already identifying and optimising multiple series of related compounds which kill TB that could be taken up by the team.

Dr Richard Seabrook, Head of Business Development at the Wellcome Trust, said: "We are pleased to be co-funding with the Bill & Melinda Gates Foundation on this exciting UK project, bringing together internationally renowned experts in the biology of infectious diseases with a first-class unit to tackle some of the world's most profound medical needs."

add to favorites email to friend print save as pdf

Related Stories

Trial for new drug-resistant TB treatment to begin

Mar 19, 2012

A global health alliance Monday unveiled plans for the first clinical tests of a new treatment regimen for tuberculosis, including for patients with resistance to existing multidrug programs.

Drug-resistant tuberculosis rife in China

Dec 11, 2008

Levels of drug-resistant tuberculosis (TB) in China are nearly twice the global average. Nationwide research published in the open access journal BMC Infectious Diseases has shown that almost 10% of Chinese TB cases are re ...

Recommended for you

Ebola: Keeping patients alive as body fights back

7 hours ago

People who shared an apartment with the first U.S. Ebola patient are emerging from quarantine healthy. And while Thomas Eric Duncan died and two U.S. nurses were infected caring for him, there are successes, ...

Study suggests altering gut bacteria might mitigate lupus

7 hours ago

Lactobacillus species, commonly seen in yogurt cultures, correlate, in the guts of mouse models, with mitigation of lupus symptoms, while Lachnospiraceae, a type of Clostridia, correlate with worsening, according to researc ...

User comments